KRAS, NRAS and BRAF mutations detected by next generation sequencing, and differential clinical outcome in metastatic colorectal cancer (MCRC) patients treated with first line FIr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy

BACKGROUND: First line triplet chemotherapy/BEV significantly improved clinical outcome of MCRC. KRAS/NRAS/BRAF mutations were evaluated by next generation sequencing (NGS) in MCRC patients treated with first line FIr-B/FOx. METHODS: KRAS exons 2-4 (KRAS(2-4)), NRAS(2-4), BRAF(15) were evaluated in...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Oncotarget
Κύριοι συγγραφείς: Bruera, Gemma, Pepe, Francesco, Malapelle, Umberto, Pisapia, Pasquale, Mas, Antonella Dal, Di Giacomo, Daniela, Calvisi, Giuseppe, Troncone, Giancarlo, Ricevuto, Enrico
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: Impact Journals LLC 2018
Θέματα:
Research Paper
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5995185/
https://ncbi.nlm.nih.gov/pubmed/29899858
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25180
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια